ReviewLeukemia & lymphoma2008
Therapeutic targeting of the BCL6 oncogene for diffuse large B-cell lymphomas.
Review in Leukemia & lymphoma, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 48 citations in OpenAlex.
- Liquid Biopsy in Hematologic Malignancies: Advances, Challenges, and Future Directions.Asia-Pacific journal of clinical oncology · 2026Review
- High-grade B-cell lymphomas: high difficulties to diagnose and treat?Hematology. American Society of Hematology. Education Program · 2025Review
- ZBTB6 promotes breast cancer progression by inhibiting ARHGAP6 transcription and modulating the STAT3 signaling pathway.Journal of translational medicine · 2025Article
- B Cell Lymphoma 6 (BCL6): A Conserved Regulator of Immunity and Beyond.International journal of molecular sciences · 2024Review
- Potential Pathogenic Impact of Cow's Milk Consumption and Bovine Milk-Derived Exosomal MicroRNAs in Diffuse Large B-Cell Lymphoma.International journal of molecular sciences · 2023Review
- Increased slow dynamics defines ligandability of BTB domains.Nature communications · 2022Article
- Discovering cell-active BCL6 inhibitors: effectively combining biochemical HTS with multiple biophysical techniques, X-ray crystallography and cell-based assays.Scientific reports · 2022Article
- Article
- AID assists DNMT1 to attenuate BCL6 expression through DNA methylation in diffuse large B-cell lymphoma cell lines.Neoplasia (New York, N.Y.) · 2020Article
- The oncogene BCL6 is up-regulated in glioblastoma in response to DNA damage, and drives survival after therapy.PloS one · 2020Article
- AID and TET2 co-operation modulates FANCA expression by active demethylation in diffuse large B cell lymphoma.Clinical and experimental immunology · 2019Article
- Inhibition of demethylase KDM6B sensitizes diffuse large B-cell lymphoma to chemotherapeutic drugs.Haematologica · 2017Article
- miR-10a inhibits cell proliferation and promotes cell apoptosis by targeting BCL6 in diffuse large B-cell lymphoma.Protein & cell · 2016Article
- A hybrid mechanism of action for BCL6 in B cells defined by formation of functionally distinct complexes at enhancers and promoters.Cell reports · 2013Article
- Targeting BCL6 in diffuse large B-cell lymphoma: what does this mean for the future treatment?Expert review of hematology · 2013Article
- Article
- Using biologic predictive factors to direct therapy of diffuse large B-cell lymphoma.Therapeutic advances in hematology · 2013Article
- Promising personalized therapeutic options for diffuse large B-cell Lymphoma Subtypes with oncogene addictions.Clinical cancer research : an official journal of the American Association for Cancer Research · 2012Review
- POK/ZBTB proteins: an emerging family of proteins that regulate lymphoid development and function.Immunological reviews · 2012Review
- Pathogenesis of human B cell lymphomas.Annual review of immunology · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
BCL6 is a transcriptional repressor often expressed constitutively in diffuse large B-cell lymphomas (DLBCL) due to mutations of its genomic locus. BCL6 mediates aberrant survival, proliferation, genomic instability and differentiation blockade in DLBCL cells. The biochemical study of BCL6 mediated gene repression has provided the basis for design of agents that inhibit BCL6 and kill lymphoma cells. The repressor activity of the BCL6 BTB domain is particularly well defined from the structural standpoint. Design of inhibitors targeting BCL6 BTB domain protein interaction surfaces appears to be an effective approach, which reactivates important BCL6 target genes and readily kills DLBCL cells. Targeting other domains of BCL6 or using histone deacetylase inhibitors to overcome BCL6 mediated repression may also be useful. Recent studies in DLBCL transcriptional signatures have revealed a subset of DLBCLs that are particularly dependent on BCL6 to maintain their survival and these patients could be candidates for clinical trials of BCL6 inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.